NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

The acquisition of Pension Insurance Corp. would effectively turn the specialist insurer into Athora's U.K. insurance business. A court-appointed special master recommended a bid backed by Gold ...

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

A match made in fast-food heaven ended this week, after high hopes and promising early results from Krispy Kreme's deal to sell doughnuts in McDonald's restaurants. Oil drillers win access to public ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

ASX health stocks jumped 1.6% over five days, with wound management house Tetratherix making its ASX debut, breaking the IPO ...

Neurizon enters global licensing agreement with ElancoNeurizon Therapeutics (ASX:NUZ) has signed an exclusive global ...

In the ongoing case of Lilly LaRoque, the woman accused of killing 17-year-old Delaney Doherty in a head-on crash nearly two ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

The actor is raising awareness of clinical trials for cancer in partnership with “GMA” sponsor Eli Lilly & Co.